COMBINATION OF DOPAMINE AGONIST AND FIRST PHASE SECRETAGOGUE FOR TREATMENT OF METABOLIC DISORDERS

• Main Author: ANTHONY H CINCOTTA
• Format: Patent
• Language: English; Japanese
• Published: 12.02.2016
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

PROBLEM TO BE SOLVED: To provide an agent that increases central dopaminergic activity plus a first-phase insulin secretagogue for the treatment of a metabolic disorder in Type 2 diabetes.SOLUTION: The present invention is relates to a method of treating a metabolic disorder or key elements of a metabolic disorder, wherein the agent that increases central dopamine activity is a dopamine agonist, and the dopamine D2 receptor agonist is bromocriptine, lisuride, hydergine, dihydroergotoxine, or other dopamine D2 receptor agonist with low or no serotonin 2B receptor agonist activity, and the first-phase insulin secretagogue includes a glucagon-like peptide-1 (GLP-1) or mimetic thereof, insulin and/or meglitinide, repaglinide, nateglinide, or a dipeptidyl peptidase inhibitor.SELECTED DRAWING: None 【課題】ＩＩ型糖尿病における代謝障害の治療のための、第一相インスリン分泌促進薬を加えた、中枢ドーパミン活性を増加する薬剤の提供。【解決手段】中枢ドーパミン活性を増加する薬剤が、ドーパミン作動薬であり、ブロモクリプチン、リスリド、ヒデルギン、ジヒドロエルゴトキシン、又はセロトニン２Ｂ受容体作動薬活性が低い又はそれがない他のドーパミンＤ２受容体作動薬であって、第一相インスリン分泌促進薬には、グルカゴン様ペプチド−１（ＧＬＰ−１）又はその模倣薬、インスリン及び／又はメグリチニド、レパグリニド、ナテグリニド又はジペプチジルペプチダーゼ阻害剤が含まれる代謝障害又は代謝障害の重要な素素を治療する方法。【選択図】なし